Lantheus wins tentative FDA sign-off for radioequivalent to LUTATHERA, edging toward U.S. launch

Lantheus Holdings said it received tentative approval from the U.S. Food and Drug Administration for an Abbreviated New Drug Application for Lutetium Lu 177 dotatate (PNT2003), a radioequivalent to the cancer therapy LUTATHERA, putting the company on a clock to convert a regulatory technical win into a commercial launch. The company disclosed the decision in a GlobeNewswire press release dated March 2 from Bedford, Mass.

The designation of tentative approval means the FDA has found the ANDA to meet statutory requirements but final clearance remains blocked by a 30-month stay tied to patent litigation and exclusivity rules, analysts and regulatory summaries note. That stay is scheduled to expire in June 2026, a date investors and competitors are watching because if it lifts Lantheus could seek final approval and, under Hatch-Waxman rules, may be eligible for 180 days of U.S. marketing exclusivity as a paragraph IV filer.

“As the first radioequivalent to LUTATHERA to receive FDA tentative approval, PNT2003 marks an important step forward in Lantheus’ work to advance treatment options for patients with GEP-NETs,” Mary Anne Heino, chief executive officer of Lantheus, said in the company release. “This milestone comes at a time when advances in imaging and evolving clinical guidelines are enabling the identification of more patients who stand to benefit from targeted radiopharmaceutical therapies. As the leading radiopharmaceutical-focused company, we remain committed to meeting this growing demand and look forward to making PNT2003 available to patients pending final FDA approval.”

LUTATHERA is indicated for somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors, covering foregut, midgut and hindgut disease. POINT Biopharma led the clinical program for the candidate in Canada, including the ongoing OZM-067 trial listed as NCT02743741, while Lantheus completed the U.S. regulatory filings, according to industry coverage of the filing and trial history.

The commercial stakes are high but binary. Investor analysis cited by market observers describes the tentative approval as a technical milestone rather than a sure commercial victory, with the June 2026 expiry of the 30-month stay the key near-term catalyst. Analysts have flagged potential patent challenges from Novartis, which holds patents on LUTATHERA that have been reported to extend into 2038, and warned that a successful legal challenge or injunction could delay or bar Lantheus from entering the market despite the tentative approval.

Market estimates vary, but at least one investor note projects PNT2003 could address a U.S. opportunity north of $500 million if Lantheus secures final approval and market access. The company says it licensed exclusive worldwide rights to PNT2003 from POINT Biopharma in late 2022; some reports place that agreement in November while the company release references December, a discrepancy noted in industry summaries.

Next steps for Lantheus include awaiting the legal timeline around the stay, pursuing final FDA clearance if the stay lifts, and preparing to launch under any 180-day exclusivity window for paragraph IV applicants. Regulators, patent holders and courts will determine whether the tentative approval becomes a commercial option for clinicians treating patients with GEP-NETs.